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Cognitive impairment 
without altered levels 
of cerebrospinal fluid biomarkers 
in patients with encephalitis caused 
by varicella‑zoster virus: a pilot 
study
Marie Eckerström1,2, Staffan Nilsson3, Henrik Zetterberg2,4,5,6, Kaj Blennow2,4 & 
Anna Grahn7,8*
Varicella‑zoster virus (VZV) is one of the most common agents causing viral infections of the central 
nervous system (CNS). VZV encephalitis is associated with severe neurological sequelae, despite 
antiviral treatment. Cognitive impairment has been reported and VZV has been associated with 
dementia. Our aim was to investigate the cognitive impairment and cerebrospinal fluid biomarkers 
in a follow‑up study of patients with VZV encephalitis. Thirteen patients with VZV encephalitis, 
diagnosed by detection of VZV DNA in cerebrospinal fluid (CSF) by PCR and concomitant symptoms 
of encephalitis, were included. Neuropsychological assessment in parallel with a lumbar puncture 
to obtain CSF was performed 1.5–7 years after acute disease. The CSF biomarkers neurofilament 
light chain (NFL), S100B, glial fibrillary acidic protein (GFAP), amyloid‑β (Aβ) 40 and Aβ42, total tau 
(t‑tau) and phosphorylated tau (p‑tau) were analysed and compared to controls (n = 24). Cognitive 
impairment was shown in the domains of executive functions and speed/attention and to a minor 
degree in the domains of learning/memory and language, indicated by a significantly poorer 
performance on seven neuropsychological test variables. No convincing evidence of alterations in 
concentrations of biomarkers in the CSF were shown. Our results indicate that patients with VZV 
encephalitis suffer from cognitive impairment long time after acute disease. Importantly, these 
impairments do not seem to be accompanied by biomarker evidence of ongoing neuronal or astrocytic 
injury/activation or induction of dementia‑related brain pathologies by the infection.
Varicella-zoster virus (VZV) is one of the most common viral agents causing central nervous system (CNS) 
infections in the Western world. The neurological complications caused by VZV include a wide spectrum of 
manifestations, such as meningitis, encephalitis, facial paralysis, myelitis, cerebellitis and stroke-like  syndromes1, 
and may occur after both primary (varicella) and reactivated (herpes zoster) VZV infection. The typical rash of 
herpes zoster is lacking in up to 40% of patients with reactivated VZV and concomitant neurological complica-
tions, which may hamper the  diagnosis1. The neurological sequelae of VZV CNS infections are reported to be 
of varying severity but are most pronounced in patients with encephalitis and include both motor and cognitive 
 dysfunctions1−4. In a French follow-up study of 15 patients with VZV encephalitis, up to half of the patients were 
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reported with moderate disability but independent in daily life 3 years after acute  disease3. The cognitive sequelae 
are so far unexplored. Only few follow-up studies comprising neuropsychological assessments are  available5–7. 
In one of these, cognitive impairment was shown 3 years after acute disease compared to controls and included 
dysfunctions in the domains of speed and attention, executive functions and learning and memory7. In addition, 
herpes zoster has been associated with dementia in recent epidemiological  studies8,9. In a 5-year follow-up study, 
patients with herpes zoster ophthalmicus had a threefold greater risk to develop dementia, most commonly of 
the Alzheimer type, compared to healthy  individuals9.
One method of identification of brain pathophysiology after CNS infections is by measuring cerebrospinal 
fluid (CSF) concentrations of various biomarkers. Neurofilament light chain (NFL) which is a marker of neuronal 
damage, is shown to be increased several months after onset of disease in patients with VZV CNS infections, 
most pronounced in patients with  encephalitis10. Changes in concentrations of S-100B and glial fibrillary acidic 
protein (GFAP) also indicate astroglial cell leakage in these  patients10,11. The Alzheimer’s disease (AD) CSF 
biomarkers amyloid-β (Aβ) 40 and Aβ42, reflecting Aβ metabolism and amyloid  plaques12, have recently been 
investigated in an in-vitro study which suggests that VZV infection may increase the toxic amyloid burden and 
contribute to amyloid-associated disease  progression13. Aβ40 and Aβ42 are generally considered markers of 
plaque pathology in AD patients but Aβ42 has also been shown to be a marker of neuroinflammation in CNS 
infections including herpes simplex encephalitis (HSE)14,15. CSF total tau (t-tau) and phosphorylated tau (p-tau) 
are other biomarkers of AD that reflect cortical axonal degeneration and neurofibrillary pathology,  respectively12, 
and both have shown to be increased in  HSE15.
In addition, some of these CSF biomarkers have been demonstrated to correlate with the results of neu-
ropsychological testing. Levels of CSF Aβ42, t-tau and p-tau have been associated with cognitive performance 
in patients with AD and mild cognitive  impairment16,17 and levels of NFL in CSF have been shown to correlate 
to cognitive performance in patients with multiple  sclerosis18.
Altogether, the knowledge of neurological sequelae in patients with VZV CNS infections, including cognitive 
impairment, is very limited. This disease needs to be further explored to better understand the neuropathogenesis 
and also the prognosis and the need of rehabilitation for these patients.
Therefore, our aim was to prospectively investigate the cognitive impairments in patients with previous VZV 
encephalitis in a long-term follow-up study and to relate the results to differences in CSF concentrations of 
biomarkers indicating CNS pathology (NFL, GFAP, S-100B, Aβ40, Aβ42, t-tau and p-tau), measured in parallel 
with the neuropsychological assessments > 1.5 years after acute disease.
Methods
Patients and controls. Patients admitted to a hospital in the region of Västra Götaland (population 1.7 
million), Sweden, between 2007–2016, were enrolled in this follow-up study. The enrolled patients had VZV 
DNA in their CSF as detected by real-time PCR and had contemporary neurological symptoms diagnosed as 
encephalitis. The encephalitis diagnosis was based on previous published  criteria10 and was defined as acute 
signs of parenchymatous brain dysfunction in addition to two of the following symptoms: fever > 38 °C, pleo-
cytosis with leukocytes > 4 × 106/L or electroencephalogram (EEG) abnormalities. At the time of acute disease 
most patients underwent magnetic resonance imaging (MRI) or computed tomography (CT) of the brain within 
the first 10 days. Antiviral treatment was in most cases given according to national recommendations in Sweden 
(Health Care Program for viral CNS infections, 2016), i.e. in encephalitis, 10–15 mg/kg t.i.d of acyclovir is given 
for 7–14 days. Clinical data are presented in Table 1.
One and a half to 7 years after acute disease caused by reactivated VZV, the patients were invited to participate 
in a follow-up study including neuropsychological testing and lumbar puncture for analysis of CSF biomarkers. At 
the time of testing they were asked about functional and cognitive impairment, current medication and alcohol 
habits. The exclusion criteria for patients were other concomitant CNS disease and other somatic diseases that 
made testing impossible.
Thirteen patients consented to participate in the study. Twelve out of 13 patients had a lumbar puncture, 
within a month before or after the neuropsychological testing. In the thirteenth patient, an 82-year-old woman 
with back problems, the lumbar puncture did not succeed. Twelve out of 13 patients underwent the neuropsy-
chological tests at a median of 41.5 months (range: 19–85) after the acute disease of VZV encephalitis. The 
patient who was not tested, a 73-year-old man, did not come for the testing because of a misunderstanding. Of 
the 12 patients who underwent neuropsychological testing, another two patients had limited Swedish language 
proficiency, which made it difficult to interpret their test results. They were excluded from the statistical analysis. 
Of these 10 patients, who were finally analysed, all had a lumbar puncture. For clinical data, see Table 1.
One patient was immunocompromised, suffering from systemic lupus erythematosus (SLE) and was receiv-
ing mycophenolic acid. During the time of testing, one patient received medication for pain with tramadol. 
Otherwise, no patients were on any medication affecting the cognitive test results. All patients that were tested 
declared very modest alcohol consumption (maximum 2–3 glasses of wine/week).
At follow-up, two patients were legally disabled, in one case regarded as a consequence of the previous VZV 
CNS infection. Six out of 13 patients were retired at normal age. Three patients had returned to work, one patient 
was enrolled as a student and one patient was unemployed. At follow-up, one patient had balance disorders and 
a hearing deficit regarded as neurological sequelae of the VZV CNS infection, which disabled him in daily life. 
The other patients had no other notable neurological deficits besides the cognitive impairments.
CSF samples from 24 non-infectious subjects, matched for age and gender, that had sought care for headaches 
were included as controls. Examination of all control subjects revealed normal neurological status, normal CSF 
cell count, normal CSF albumin concentration and no clinical signs of herpes zoster.
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CSF analysis. At the time of acute disease, non-centrifuged CSF was analysed for cell counts and VZV DNA 
by a quantitative in-house PCR with a sensitivity of 100 copies/ml of VZV  DNA1. At follow-up 1.5 to 7 years after 
the acute infection, non-centrifuged CSF was analysed for cell counts. After centrifugation, supernatants were 
aliquoted and stored at –70 °C pending biochemical analyses. All CSF samples were then analysed on one occa-
sion using one batch of reagents for the following biomarkers: GFAP, NFL, S-100B, Aβ40, Aβ42, t-tau and p-tau. 
The concentrations of GFAP and NFL were determined using previously described in-house ELISA methods, 
shown to specifically react with GFAP and NFL in CSF, and having analytical sensitivity high enough to measure 
these proteins in any CSF samples, also from healthy  people19,20. Detection levels for the NFL and GFAP in-
house ELISA methods are reported to 78 ng/l and 16 ng/l  respectively19,20. CSF levels of S-100B were determined 
using the cobas Elecsys system and the S100B reagent kit (Roche Diagnostics, Basel, Switzerland). Aβ40, Aβ42, 
t-tau and p-tau concentrations were measured using Lumipulse G β-amyloid 1–42 (no. 230336), β-amyloid 
1–40 (no. 231524), total Tau (no. 230312) and pTau 181 (no. 230350) assays on the fully automated LUMIPULSE 
G600II instrument according to instructions from the manufacturer (Fujirebio, Ghent, Belgium). The limit of 
detection for Lumipulse G total Tau and pTau 181 are 141 ng/l and 0.28 ng/l, respectively, according to manu-
facturer (Fujirebio, Ghent, Belgium). The coefficients of variation for all biochemical analyses were below 10%.
Neuropsychological testing and procedure. A neuropsychological test battery including 11 tests and 
comprised of 18 test variables was used to capture cognitive impairments from different cognitive domains. The 
battery comprises the domains of speed and attention (symbol digit modalities test (SDMT); trail making test A 
(TMT A); continuous performance test (CPT-II) reaction time), learning and episodic memory (California verbal 
learning test (CVLT); brief visuospatial memory test revised (BVMT-R), visuospatial functions (block tapping 
test; the silhouettes subtest from the visual object and space perception battery), language (Boston naming test 
(BNT); category fluency animal naming) and executive functions (continuous performance test (CPT-II) omis-
sions and commissions; trail making test B (TMT B); letter-number sequencing). The neuropsychological tests 
are further described in Table 2. The tests were administered by psychologists in training, supervised by a spe-
cialized neuropsychologist. All tests were administered in a standardised sequence designed to reduce the risk 
of contamination in the memory tests. The patients’ test results were analysed in relation to previously published 
age- and education stratified normal data, see Table 2 for references.
Statistical analysis. Differences in biomarker log concentrations between patients and matched controls 
were analysed with linear mixed models. The patients’ cognitive test results were transformed into T-scores using 
previously published age- and education stratified normal data (see Table 2) and directed so that a better perfor-
mance equals a higher T-score. Differences between T-scores and norm values (i.e. mean 50 and standard devia-
tion 10) were analysed by one-tailed one-sample t-tests. Association between age and T-scores were analysed 
with Pearson correlation tests. Spearman’s rank test was used for correlations between biomarker concentrations 
and T-scores.
Table 1.  Demographic data of 13 patients with previous encephalitis caused by reactivated varicella-zoster 
virus. CT computer tomography, Iv intravenous, ND not done, LP lumbar puncture, MRI magnetic resonance 
imaging. a Oral treatment with valacyklovir 1 g × 3, 7 days. b Only qualitative PCR analysis was performed. 
c Limited Swedish language.
Gender/age at follow-up Education (years)
Viral load at acute 
disease (copies/ml) MRI/CT at acute disease Iv treat-ment (days)
Follow-up (mo. after 
symptom onset)
LP/cognitive testing at 
follow-up
F/82 7 100 MRI ND/CT neg 4 85 ND/Yes
F/63 4,5 1,600,000 MRI and CT neg 7 53 Yes/Yesc
M/28 12 25,000 MRI and CT neg 8 42 Yes/Yes
F/24 12 400 MRI ND/CT neg 14 41 Yes/Yes
M/85 7 6,300
Wide-spread white mat-






larly and subcortically 





and occipital ischemic 
changes
13 91 Yes/Yes
F/34 13 25 million ND 12 39 Yes/Yes
M/74 10 500,000 ND 6 33 Yes/Yes
F/35 16 12,600 MRI ND/CT neg 10 36 Yes/Yes
M/32 15 31,600 MRI and CT neg 10 50 Yes/Yes
M/58 5 NDb MRI and CT neg 14 20 Yes/Yesc
M/73 ND 316,000 MRI neg/CT ND 11 19 Yes/ND
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Results
CSF biomarkers. Significantly increased concentrations of NFL, indicating neuronal damage, were shown 
in the patients with VZV encephalitis (n = 12) (median 549  ng/l; IQR 371–1,205) compared with controls 
(n = 24) (497 ng/l; 345–989) (p = 0.025) (Fig. 1a). This result was depending on only two patients with higher 
NFL concentrations compared with their matched controls. One of them was a 34-year-old woman with SLE 
with involvement of heart, lungs and kidneys. There was no evidence of CNS involvement of her SLE but this 
cannot be ruled out. The other patient with increased NFL concentrations was an 85-year old man with pros-
tate cancer, classified as moderately differentiated carcinoma, but otherwise reported to have an active physical 
and social daily life. No differences in concentrations of GFAP nor S-100B, indicating astroglial damage, were 
shown in the patients with VZV encephalitis compared with controls (Fig. 1b,c). The median value of GFAP was 
390 ng/l (IQR 324–536) for the patients with encephalitis and 279 ng/l (211–403) for the controls (Fig. 1b) and 
the median value of S100 was 0.66 μg/l (0.52–0.86) for the patients with encephalitis and 0.56 μg/l (0.45–0.71) 
for the controls (Fig. 1c). No alterations in concentrations of the AD biomarkers Aβ40, Aβ42, t-tau, p-tau nor 
in Aβ42/Aβ40 ratios were detected in the patients with VZV encephalitis compared with controls (Fig. 1d–g). 
The median value of Aβ40 was 8210 ng/l (IQR 7,480–12,404) for the patients with encephalitis and 10,247 ng/l 
(7,630–13,630) for the controls (Fig. 1d). The median value of Aβ42 was 710 ng/l (634–1,096) for the patients 
with encephalitis and 786 ng/l (614–1,105) for the controls (Fig. 1e). The median value of p-tau was 30 ng/l (20–
40) for the patients with encephalitis and 30 ng/l (24–36) for the controls (Fig. 1f). The median value of t-tau was 
214 ng/l (140–455) for the patients with encephalitis and 206 ng/l (156–267) for the controls (Fig. 1g). Analysed 
as a group, the concentrations of NFL, GFAP, S-100B, Aβ40, Aβ42, t-tau and p-tau in the CSF of the controls, were 
all within the reference values established in the Clinical Neurochemistry Laboratory in Mölndal, Sweden, i.e., 
for CSF NFL < 380 ng/l (< 30 years), < 560 ng/l (30–39 years), < 890 ng/l (40–59 years), < 1850 ng/l (> 59 years); 
for CSF GFAP < 750 ng/l (20–60 years), < 1250 ng/l (> 60 years); for CSF S100B < 1.7 μg/l (> 20 years); for CSF 
Aβ42 > 620 ng/l; for CSF Aβ42/40 ratio > 0.061; for CSF t-tau < 360 ng/l (20–50 years), < 479 ng/l (> 50 years; and 
for CSF p-tau < 61 ng/l21. In addition, no correlations of biomarker concentrations and neuropsychological test 
results were shown.
Neuropsychological tests. The patients with VZV CNS infection performed significantly worse (p < 0.05) 
compared with the normal mean scores on seven out of 18 analysed neuropsychological test variables (Fig. 2): 
on 3 out of 4 test variables in the executive function domain: CPT omissions (p < 0.001), letter-number sequenc-
ing (p = 0.018), TMT B (p < 0.001); 2 out of 3 test variables in the speed/attention domain: CPT hit reaction 
Table 2.  Neuropsychological tests, domains, functions and source of normal data.
Cognitive domain Neuropsychological test Task and function Specific variables analysed References
Executive functions
Continuous performance test (CPT) II
Computerized target response task. Involves 
several aspects of sustained and selective 
attention, executive control, and reaction 
time
Omissions (failure to respond to target); 
commissions (response to non-target); reac-




Recall a series of numbers in increasing order 
and letters in alphabetical order. Involves 
working memory, attention, executive control
Sum of correct responses 33
Trailmaking test B
Timed sequencing task, alternating letters 
and numbers. Visual scanning, psychomotor 
speed, cognitive flexibility
Time in seconds 34
Learning and memory
California verbal learning test (CVLT)
Word list learning (trial 1–5) and recall. 
Involves verbal episodic learning and 
memory
Total learning (sum of correct responses in 
trial 1–5); immediate recall; delayed recall
35
Brief visuospatial memory test revised 
(BVMT-R)
Timed spatial figure learning (trial 1–3) and 
recall. Involves spatial episodic learning and 
memory
Learning (trial 1–3); delayed recall 36
Speed and attention
Trailmaking test A Timed sequencing task, numbers. Visual scanning and psychomotor speed Time in seconds
34
Symbol digit modalities test
Timed substitution task using a reference 
key. Involves attention, psychomotor speed, 
perceptual speed, visual scanning
Sum of correct responses 37
Continuous performance test (CPT) II See above Reaction time (hit RT—average speed of correct responses)
32
Language
Boston naming test Picture naming task. Involves confrontational word retrieval Sum of correct responses
38
Category fluency (animals)
Timed word generation within a semantic 
category. Involves verbal fluency and execu-
tive control
Sum of correct responses 39
Visuospatial functions
Block tapping test
Tapping spatially separated blocks in prede-
fined sequences of increasing length. Involves 
visuospatial working memory
Sum of correct responses 33
Silhouettes (VOSP battery)
Picture task, identifying objects and animals 
presented as silhouettes. Involves visuospatial 
perception
Sum of correct responses 40
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Figure 1.  (a–e) Concentrations of cerebrospinal fluid biomarkers in patients with encephalitis caused by 
reactivated varicella-zoster virus (n = 12), 41 months (range: 19–85) after acute disease, and their controls 
(n = 24) (a) neurofilament light chain (NFL), (b) glial fibrillary acidic protein (GFAP), (c) S-100B, (d) amyloid-β 
40 (Aβ40), (e) amyloid-β 42 (Aβ42), f) phosphorylated tau (p-tau), g) total tau (t-tau).
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time (p < 0.001), TMT A (p < 0.001); 1 out of 7 test variables in the learning/memory domain: BVMT-R trial 1 
(p = 0.033); and 1 out of 2 test variables in the language domain:; BNT (p = 0.033). There were no significant dif-
ferences within the visuospatial domain. Individual test scores for each participant are plotted in Fig. 3.
The neuropsychological test results were compared with normative data from different previously published 
sources that were already adjusted for age and education. However, due to the varying ages in our study partici-
pants, we also checked for associations between the participants’ T-scores and age. Older individuals performed 
worse in comparison with their age peers compared to younger individuals on three neuropsychological tests: 
CPT omissions (r = -0.95; p < 0.001), CPT reaction time (r = -0.74, p = 0.01) and CVLT delayed recall (r = -0.72, 
p = 0.02). On the BVMT-R trial 1, older individuals performed slightly better compared to younger individuals 
(r = 0.65, p = 0.04).
Discussion
This is one of few long-term studies evaluating cognitive impairment in patients with VZV encephalitis and 
also including investigations of associations between cognitive impairment and CSF biomarkers. We found that 
the patients with VZV encephalitis had signs of impairment in the domains of executive functions, speed and 
attention, learning and memory and language indicated by a significantly poorer performance on seven different 
neuropsychological test variables within these four domains. The most significant impairments were shown in 
the domains of executive functions and speed and attention, while a less pronounced impairment was shown 
in the domains of learning and memory and language. Importantly, these impairments were not accompanied 
by biomarker evidence of ongoing neuronal or astrocytic injury/activation or induction of AD-related brain 
pathologies (increased p-tau or decreased Aβ42/Aβ40 ratio) by the infection.
The results of the neuropsychological assessment are in line with two other follow-up  studies5,7. The first 
one was a study of fourteen patients with different VZV CNS  manifestations7 and the second one included nine 
patients with VZV  encephalitis5. In both these studies, signs of cognitive impairment were shown in the domains 
of speed and attention and learning and memory. In the most recent study of fourteen  patients7, cognitive 
impairment was also reported in the domain of executive functions, as in our study. However, a third study of 
eight patients with VZV encephalitis revealed poorer performance in only one test in the domain of visuospatial 
 function6. Yet, all conducted studies include a small number of participants, and in the second and third study, 
only few patients were followed-up after 1 year, making the results difficult to interpret. Nevertheless, our results 
strengthen the notion that patients with VZV CNS infection may be impaired in several cognitive domains a long 
time after acute disease and the impairment seems to predominantly include the domains of executive functions 
and speed and attention, and to some extent learning and memory and language.
As cognitive impairment may be associated to altered concentrations of CSF biomarkers, we aimed to inves-
tigate this relation. NFL concentrations were increased in the patients with VZV encephalitis compared with 
controls. However, this result was depending on only two patients of whom at least one of them had a disease 
that may involve CNS, although this 34-year-old woman had no evidence of CNS involvement of her SLE. The 
other patient was an 85-year-old man with prostate adenocarcinoma where CNS involvement is rare but do 
occur. Hence, we do not interpret this increase in CSF NFL as evidence of an association to VZV, even though it 
CPT−II omissions 
CPT−II commissions 
CPT−II reaction time 
Letter−number sequencing 
CVLT total learning 
CVLT immediate recall 
CVLT delayed recall 
BVMT−R trial 1 
BVMT−R trial 2 
BVMT−R trial 3 
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Figure 2.  Neuropsychological test results for the total study group, presented as T-scores. P-values indicate 
difference between study group and normative scores.
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cannot be ruled out. Increased concentrations of NFL and GFAP have previously been reported in patients with 
VZV CNS  infection10,11 and were most pronounced in VZV encephalitis. Similar findings have been reported 
in patients with other CNS infections, such as HSE, tick-borne encephalitis (TBE) and  neuroborreliosis22,23. 
However, in these studies the CSF biomarkers were only measured up to the first few months after acute disease 
and the increased levels were presumably corresponding to the acute CNS damage. If virus is cleared from CNS 
with the help of antivirals, one could expect that no ongoing neuronal or astroglial damage occur. In autopsy 
reports VZV is only rarely detected in brain tissue, in contrast to herpes simplex type-1(HSV-1)24.
The other CSF biomarkers investigated in this study, Aβ40, Aβ42, t-tau and p-tau, are most commonly used 
to characterize AD and other dementias. We could not detect any alterations in these biomarkers long time 
after acute disease that would indicate a connection between VZV to AD or other dementias. Nevertheless, as 
previously mentioned, patients with herpes zoster have been shown in recent large epidemiological studies to 
run a greater risk of developing dementia, in particular  AD8,9. A suggested mechanism for this link, although 
not supported by our results, is increased toxic amyloid burden by extracellular aggregation of cellular peptides 
into amyloid fibrils mediated by VZV glycoprotein B  peptides13. Among other CNS infections, patients with HSE 
have expressed an AD-like biomarker pattern with regard to increased CSF t-tau, p-tau and decreased Aβ4215. 
Several authors have proposed a connection between HSV-1 and development of  AD15,25,26. However, this AD-
like biomarker pattern may also be an expression of the direct cytotoxic effect that HSV-1 exerts on neurons with 
inflammation and focal necrosis of brain tissue merely at acute  disease27.
Despite the lack of altered concentrations of specific CSF biomarkers there may still exist an increased vulner-
ability of developing dementia as mild cognitive impairment is one of the risk  factors28. Both AD and other forms 
of dementia is preceded by mild cognitive impairment. If biomarker alterations are lacking, other dementia forms 
than AD, e.g. vascular dementia, are more likely the cause of mild cognitive  impairment28,29. VZV encephalitis is 
suggested to be primarily a vasculopathy with vessel wall  infection30 and in the context of our results a progres-
sion to dementia may not necessarily be in the form of AD. However, further studies are needed to investigate 
the association of VZV to AD and other dementias.
Lastly, several cognitive abilities are negatively affected by aging, such as processing speed and abilities within 
the memory, language, visuospatial, and executive function  domains31. The participants in our study were of 
varying ages, and their test scores were analysed as T-scores in relation to normative age- and education adjusted 














































































































































































Figure 3.  (a–e) Neuropsychological test results within five cognitive domains (a) executive functions, (b) 
learning and memory, (c) speed and attention, (d) language, (e) visuospatial functions, plotted as individual 
T-scores.  oper circle = younger ages (24; 28; 32; 34; 35 years); filled circle = older ages (52, 74, 76, 82, 85 years). 
Significant group differences compared to normal data (Fig. 2) are indicated by * (p < 0.05) or ** (p < 0.001). 
BNT Boston naming test, BVMT-R Brief visuospatial memory test revised, Cat. Category, CPT continuous 
performance test, CVLT California verbal learning test, SD standard deviation, SDMT Symbol digit modalities 
test, seq. sequencing; TMT Trail making test, VOSP Visual object and space perception.
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Especially, older study participants had lower T-scores on CPT omissions (failure to respond when asked to 
respond on certain letters on a screen) and CPT reaction time. These results indicate that the older individuals 
performed worse on these measures of processing speed and attention compared to age peers, than the younger 
study participants whose results were largely on par with expected levels for age peers. Possibly, these results 
could be related to cognitive difficulties caused by factors other than VZV infection in our older individuals, 
and the number of participants is too small to make firm conclusions. If replicated, the results could suggest that 
VZV infection lead to more impairment in the speed/attention cognitive domain in older individuals compared 
to in younger individuals.
There are some limitations of this study, such as small number of participants and no CSF biomarker data 
or neuropsychological assessment at the time for acute disease. In addition, this study was conducted without 
controls for the neuropsychological assessment. Previously published age- and education adjusted normative 
data were used instead.
In conclusion, our study demonstrates that patients with VZV encephalitis suffer from cognitive impairment 
in the domains of executive functions and speed and attention, and to some extent learning and memory and 
language, several years after acute disease. However, no convincing evidence were shown of alterations in the 
CSF biomarkers GFAP, NFL, S-100B, Aβ40, Aβ42, t-tau or p-tau indicating an association to ongoing neuronal 
damage or dementia.
Ethical approval. The Medical Ethics Committee at Gothenburg University approved the study (EPN 229–
14) and informed consent was obtained from all patients. The study has been performed in accordance with the 
ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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